CN101926878B - Chinese medicinal composition for treating osteoarthritis and preparation method thereof - Google Patents
Chinese medicinal composition for treating osteoarthritis and preparation method thereof Download PDFInfo
- Publication number
- CN101926878B CN101926878B CN201010190202.9A CN201010190202A CN101926878B CN 101926878 B CN101926878 B CN 101926878B CN 201010190202 A CN201010190202 A CN 201010190202A CN 101926878 B CN101926878 B CN 101926878B
- Authority
- CN
- China
- Prior art keywords
- radix
- group
- chinese medicine
- percent
- decocting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a Chinese medicinal composition for treating knee pain osteoarthritis, which comprises 9 to 15 percent of prepared rhizome of rehmannia, 7 to 14 percent of desertliving cistanche, 9 to 15 percent of drynaria rhizome, 9 to 15 percent of epimedium herb, 6 to 13 percent of Chinese angelica, 11 to 15 percent of white paeony root, 9 to 15 percent of raw astragalus, 5 to 9 percent of licorice root and 9 to 15 percent of two-tooth achyranthes root. A preparation method comprises the following steps of: drying and crushing the desertliving cistanche to fine powder of 80 to 120 meshes; decocting the rest medicaments twice by adding water, combining two times of filtrate, and concentrating the filtrate under reduced pressure to form thick paste with a relative density of 1.35 to 1.40 at the temperature of 50 DEG C; and finally mixing the thick paste and the desertliving cistanche fine powder and collecting the paste, and drying and crushing the paste into medicinal powder so as to obtain the Chinese medicinal composition. The medicaments mainly have the effects of tonifying liver and kidney and strengthening tendons and bones, and integrate the effects of replenishing qi and blood, dispelling wind and dampness and relieving pain so as to achieve the effect of treatment.
Description
Technical field
The invention belongs to Chinese drug preparation technique field, relate to a kind of Chinese medicine composition for the treatment of gonalgia osteoarthritis, also relate to the preparation method of this Chinese medicine composition.
Background technology
Osteoarthritis, claim again proliferative arthritis, the main pathology of osteoarthritis is changed into cartilage degeneration and disappearance, and edge, joint ligament adheres to place and subchondral bone qualitative response hypertrophy forms hyperosteogeny, and causes thus arthralgia, stiff deformity and dysfunction.Osteoarthritis clinically, can be divided into constitutional and Secondary cases two classes.Spontaneous osteoarthritis, refers to osteoarthritis that can not check the cause of disease by current all inspection methods, and the osteoarthritis of indication belongs to this class conventionally; Secondary cases osteoarthritis refers to that, on the basis of other various causes of disease or disease, the pathological changes of bringing out, as wound, rheumatoid arthritis, nerve and endocrinopathy etc.The pathological changes of this class osteoarthritis is relatively limited to, and Heberden node does not occur together.The crowd who repeatedly makes articular strain is the high-risk group who suffers from osteoarthritis, as foundry worker, miner and bus driver etc.Be the modal a kind of osteoarthritis of middle-aged and elderly people equally, be apt to occur in knee joint, hip and joints of hand, especially the highest with knee joint sickness rate.The medicine for the treatment of in the market osteoarthritis mainly contains: (1) hyaluronate sodium: be the main component of articular cavity synovial fluid; for one of composition of cartilage matrix; play lubrication in joint; reduce the friction between tissue, after injecting in articular cavity, can obviously improve the inflammatory reaction of synovial tissue, strengthen toughness and the lubricating function of joint fluid; Saving cortilage cartilage; promote healing and the regeneration of articular cartilage, alleviating pain, the mobility in increase joint.(2) glucosamine: be the most important monosaccharide of poly-glucosamine (GS) and proteoglycan in formation articular cartilage substrate, normal person can synthesize GS by the amination of glucose, but GS biosynthesis block or deficiency in osteoarthritis person's chondrocyte, cause cartilage matrix soften and follow the string, collagen fiber structure destroys, and cartilage surface lacuna increases to be made skeleton wearing and tearing and destroys.The pathogenesis of glucosamine osteoarthritis capable of blocking, impel the synthetic proteoglycan with normal configuration of chondrocyte, and suppress the generation of the enzyme (as collagenase, phospholipase A2) of damaged tissue and cartilage, reduce the damage of chondrocyte, improve joint motion, alleviate arthralgia, delay the osteoarthrosis inflammation course of disease.(3) non-steroidal antalgic anti-inflammatory agent: can suppress the synthetic of Cycloxygenase and prostaglandin, to anti-inflammatory response, alleviate hydrarthrosis and pain.Treatment osteoarthritis adopts at present physiotherapy and medicine, function is comparatively single, just temporarily plays and alleviates ailing effect, and its curative effect and cure rate are all lower, are difficult for eradicating, and medical expense is high.
Summary of the invention
The object of this invention is to provide a kind of Chinese medicine composition for the treatment of gonalgia osteoarthritis, solved prior art treatment knee joint osseous arthritis curative effect and cure rate is lower, be difficult for the problem eradicated, medical expense is high.
Another object of the present invention is to provide the preparation method of above-mentioned Chinese medicine composition.
The technical solution adopted in the present invention is that a kind of Chinese medicine composition for the treatment of gonalgia osteoarthritis, is characterized in that, by weight percentage, formed by the raw material of Chinese medicine of making below active ingredient: Radix Rehmanniae Preparata 9-15%, Herba Cistanches 7-14%, Rhizoma Drynariae 9-15%, Herba Epimedii 9-15%, Radix Angelicae Sinensis 6-13%, the Radix Paeoniae Alba 11-15%, Radix Astragali 9-15%, Radix Glycyrrhizae 5-9%, Radix Achyranthis Bidentatae 9-15%, above each component percentage by weight sum is 100%.
Another technical scheme of the present invention is, the preparation method of above-mentioned Chinese medicine composition is provided, and comprises following operating procedure:
Step 1,
Take each raw material according to following percentage by weight: Radix Rehmanniae Preparata 9-15%, Herba Cistanches 7-14%, Rhizoma Drynariae 9-15%, Herba Epimedii 9-15%, Radix Angelicae Sinensis 6-13%, the Radix Paeoniae Alba 11-15%, Radix Astragali 9-15%, Radix Glycyrrhizae 5-9%, Radix Achyranthis Bidentatae 9-15%, above each component percentage by weight sum is 100%;
Step 2,
Herba Cistanches is dried and crushed into 80-120 object fine powders for subsequent use;
Step 3,
Radix Rehmanniae Preparata, Rhizoma Drynariae, Herba Epimedii, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Astragali, Radix Glycyrrhizae and Radix Achyranthis Bidentatae eight taste Chinese medicines are added to decocting to be carried twice, add for the first time the decocting of 8-12 times of amounts of eight taste Chinese medicine total amounts to boil 1-3 hours, filter, add for the second time the decocting of 6-10 times of amounts of eight taste Chinese medicine total amounts to boil 1-2 hours, filter, merge filtrate twice, then filtrate is evaporated to relative density at 50 DEG C is 1.35-1.40 thick paste;
Step 4,
Thick paste is mixed with Herba Cistanches fine powder and receive cream, be dried and crushed into 80-120 object medicated powder, to obtain final product.
Wherein, add newborn sugar and starch in step 4 in the medicated powder making, mix, granulate, dry, granulate, makes capsule.
Wherein, in the medicated powder making, add starch in step 4, mix, granulate, dry, compacting in flakes, makes tablet.
The invention has the beneficial effects as follows, therapeutic effect is good, and cure rate is high, easily eradicates.Motherland's medical science thinks that osteoarthritis belongs to " arthromyodynia " category, though think that through clinical practice for many years osteoarthritis dialectical do not go out arthromyodynia category, but patient with age often, sick for a long time and be mainly in that health bears a heavy burden or movable more joint, therefore think both liver and kidney deficiency, deficiency in both Qi and blood, muscle bone no hard is the main pathogenesis for primary disease, medicine of the present invention is based on taking invigorating the liver and kidney, bone and muscle strengthening as main, takes into account replenishing QI and blood, wind-damp dispelling, removes arthralgia pain, to reach the effect for the treatment of.
Detailed description of the invention
Below in conjunction with detailed description of the invention, the present invention is described in detail.
One, the prescription of Chinese medicine composition of the present invention and content
The present invention is made up of the raw material of making below active ingredient by weight percentage: Radix Rehmanniae Preparata 9-15%, Herba Cistanches 7-14%, Rhizoma Drynariae 9-15%, Herba Epimedii 9-15%, Radix Angelicae Sinensis 6-13%, the Radix Paeoniae Alba 11-15%, Radix Astragali 9-15%, Radix Glycyrrhizae 5-9%, Radix Achyranthis Bidentatae 9-15%, above each component percentage by weight sum is 100%.
Two, each prescription function and function cure mainly
1, the function of various prescriptions in the Chinese medicine composition of invention:
Herba Epimedii, warming the kidney to invigorate YANG, bone and muscle strengthening, wind-damp dispelling; Herba Cistanches, kidney-replenishing, benefiting essence-blood; The two is monarch drug altogether, with liver and kidney tonifying, bone and muscle strengthening;
Radix Astragali, invigorating QI to consolidate the body surface resistance; Radix Angelicae Sinensis, enriches blood; The two plays the effect of invigorating QI and blood altogether for ministerial drug;
Rhizoma Drynariae, invigorate blood circulation continuous muscle, invigorating the kidney and strengthening the bones, to help invigorating the liver and kidney, bone and muscle strengthening, and bring into play the merit of replenishing QI and blood, is adjuvant drug; Radix Achyranthis Bidentatae, returns Liver and kidney two warps, can invigorating the liver and kidney, bone and muscle strengthening, and there is again promoting blood circulation to restore menstrual flow, draw the descending effect of (fire) blood, property is kind descending, is adjuvant drug; Radix Rehmanniae Preparata, vital essence replenishing and marrow benifiting, aches with controlling waist of lower part knee joint, is its speciality, therefore also for making medicine; The Radix Paeoniae Alba, Radix Glycyrrhizae coordinate, and relieving spasm to stop pain, altogether for making medicine.
Take a broad view of full side, be based on taking invigorating the liver and kidney, bone and muscle strengthening as main, take into account replenishing QI and blood, wind-damp dispelling, remove arthralgia pain; Make laws tight, treating both the principal and secondary aspects of a disease, the pathogenesis that hits, has caught the main idea of preventing and treating osteoarthritis.
2, function cures mainly:
Medicine invigorating the liver and kidney of the present invention, replenishing QI and blood.For osteoarthritis deficiency of the liver and kindey, deficiency of qi and blood card, disease is seen arthroncus, numbness, pain, limitation of activity.
3, usage and dosage:
The capsule that Chinese medicine composition of the present invention for oral administration is made, one time 4～6, every containing crude drug 0.4g, 3 times on the one, one after each meal, two weeks was 1 course for the treatment of.
Three, various experiments and the result of Chinese medicine composition of the present invention
(1), pharmacodynamic experiment
The impact of Chinese medicine composition of the present invention on TNF-α and IL-1, IL-6 content results in rabbit knee osteoarthritis joint fluid:
1), laboratory animal: healthy Japanese screech owl White Rabbit of 4 monthly ages, 72, male, body weight is 1.8-3.5kg, provides (credit number SCXK Shan 2008-008) by Xi'an Jiaotong University Medical College's Experimental Animal Center.Before the experiment of each group White Rabbit, raise 1 week in animal housing, under room temperature, raising feed, drinking-water are not limit.
Experimental drug and reagent: Chinese medicine composition of the present invention (prescription composition: Radix Rehmanniae Preparata, Radix Astragali, Herba Epimedii, each 15 parts of Rhizoma Drynariae, Herba Cistanches, each 10 parts of Radix Achyranthis Bidentatae, 6 parts, Radix Glycyrrhizae, 8 parts of Radix Angelicae Sinensis, 12 parts of the Radix Paeoniae Albas), provided by Chinese medicine pharmacy of Affiliated Hospital of Shaanxi College of Traditional Chinese Medicine, get above-mentioned ingredients according to prescription ratio, add water 10 times to measure to decoct and extract twice, merge extracted twice liquid, being evaporated to relative density is 1.1(50 DEG C) extractum, add ethanol precipitation, make concentration of alcohol reach 60%, get supernatant, decompression recycling ethanol, precipitate concentrating under reduced pressure is dry, be ground into fine powder for subsequent use, getting before use corresponding dosage medicated powder is dissolved in water and carries out administration.Glucosamine hydrochloride capsule (Zhejiang Cheng Yi Pharmaceutical Co., Ltd, batch number: 20090503, authentication code: the accurate word H20060748 of traditional Chinese medicines).Rabbit tumor necrosis factor-alpha enzyme-linked immunoassay kit is provided by R & D company of the U.S..
Experiment equipment: HB-2 type Olympus microscope, CBQ-II type Design of Thin-sliced Cutting Machine for Hard Materials and high speed DL-8R freezing centrifuge, ELX808IU microplate reader are provided by the U.S. (FCC Compliance, USA).
2), test method:
1. animal grouping and model are prepared 72 laboratory animals and are divided at random dosage group (D group), Chinese medicine small dose group of the present invention (E group), glucosamine hydrochloride capsule matched group (F group) in blank group (A group), model group (B group), Chinese medicine high dose group of the present invention (C group), Chinese medicine of the present invention.Except blank group, other groups all adopt that Gypsum Fibrosum is tubular fixes 6 weeks, cause rabbit knee osteoarthritis models at different.In modeling simultaneously, Chinese medicine composition group of the present invention (C group, D group and E group) and matched group (F group) are given respectively and the Chinese medicine composition of the present invention of various dose and glucosamine hydrochloride capsule gavage 4 weeks, after modeling 6 weeks, the changes of contents of TNF-α and IL-1, IL-6 changes of contents in row histological examination and application ELISA method mensuration joint fluid.
What gavage scheme started from modeling starts gavage on the 1st day, treatment time is 4 weeks, gavage situation is as follows: C, D, E group every day is respectively to be equivalent to the Chinese medicine composition gavage of the present invention of 20 times, 10 times of clinical adult's dosage (adult's dosage is equivalent to crude drug amount 4.8g) and 6 times, point sooner or later gavages for twice; F group is divided and is sooner or later gavaged for twice to be equivalent to clinical adult's dosage (adult's dosage is equivalent to crude drug amount 4.8g) aminoguanidine hydrochloride glucose carbohydrate gum capsule gavage of 5 times every day; Model group (B group) every day to be to hold the normal saline gavage of (2ml/d) with medication group (C, D, E, F group) etc., point sooner or later gavages for twice; Blank is organized not gavage.During giving White Rabbit gavage, White Rabbit has no adverse reaction and death condition occurs.
3), test item and experimental result:
Animal ordinary circumstance and knee joint endoprosthesis cartilage general form: Normal group (A group) the White Rabbit mental status is good, and hair color is without ANOMALOUS VARIATIONS, and stimulation is to external world more responsive, modeling knee joint plaster slab is fixing safe; The withered original text of model control group (B group) White Rabbit hair color, tarnish, spontaneous activity obviously reduces, and the sensitivity stimulating to external world significantly reduces, and modeling knee joint plaster slab is fixing safe; Chinese drug-treated group (C, D, E group) and glucosamine group (F group) the White Rabbit mental status are good compared with model control group (B group), hair color is moist compared with model control group (B group), stimulation is more responsive to external world, and spontaneous activity increases compared with model control group (B group), and modeling knee joint plaster slab is fixing safe.
Observed result under light microscopic: modeling, after 6 weeks, is respectively organized rabbit and put to death, and dissects the left knee joint of rabbit, the morphological change of perusal articular cartilage and synovial membrane.A group rabbit knee cartilage outward appearance is blue and white, and color and luster is bright, and smooth surface, without softening and be full of cracks, without cartilage defect, has moist feeling, and that touches is harder, and synovial membrane color and luster is normal.There is significant morphological change in B group rabbit knee cartilage, articular cartilage obviously loses former glossy, jaundice, opaque, cartilage surface is imperfect, more coarse, and that touches is softer, and due to intestine erosion and ulcer face appears in heavy burden region, substrate is darker, can deeply reach cartilage holostrome, occur that cartilage in various degree strips off, subchondral bone exposes, hyperosteogeny generates, and cartilage synovial membrane exists swelling in various degree, hyperemia; Each group of (C, D, E group) animal articular cartilage of prophylactic treatment has color and luster in various degree to change, hyperosteogeny, bone cyst form, and shallow erosion appears in cartilage joint face, and the cartilage defect of part specimen reaches cartilage middle level deeply, occur that cartilage strips off, but degree is starkly lower than B group.In matched group F group and Chinese medicine, dosage group (D group) preventive and therapeutic effect is approximate.
TNF-alpha levels measurement result, in table 1, as seen from the table, more blank group of (A group) obviously higher (P < 0.001) of model group (B group) TNF-alpha levels, illustrates that it may be one of factor of osteoarthritis generation that TNF-alpha levels raises; Can find out that A group TNF-alpha levels is compared with the obvious decline of model group (B group) (P < 0.01) simultaneously, illustrate that Chinese medicine composition of the present invention may treat early stage osteoarthritis by reduction TNF-alpha levels.
The impact of table 1 medicine of the present invention on TNF-alpha content in rabbit joint fluid
| Group | Number of cases | TNF-ɑ（μg/L） |
| A group (blank group) | 12 | 0.001±0.000※ |
| B group (model control group) | 12 | 16.136±2.336▲ |
| C group (Chinese medicine high dose group) | 12 | 1.587±0.657* |
| D group (dosage group in Chinese medicine) | 12 | 5.023±0.969* |
| E group (Chinese medicine low dose group) | 12 | 11.785±2.052* |
| F group (glucosamine hydrochloride Capsules group) | 12 | 5.018±0.949★□ |
Note: A group and relatively ※ P<0.05 of B group; B group and C, D, E, F organize comparison ▲ P<0.05; Between C, D, E group, compare between two * P<0.05; F group and C, relatively ★ P<0.05 of E group; F group and relatively P>0.05 of D group.P value represents statistical value; P<0.05 representative has statistical significance; P>0.05 represents not statistically significant.
IL-1 content results in joint fluid: in table 2, B group and C, D, E, F group relatively have significant difference (P<0.05).F group has significant difference with E group, and in prompting glucosamine hydrochloride Capsule in Reducing rabbit joint fluid, the effect of IL-1 content is better than Chinese medicine low dose group of the present invention.Between C, D, E group, relatively have between two significant difference, illustrate that Chinese herb on the prevention group of the present invention increases with dosage, the effect that reduces IL-1 content in rabbit joint fluid strengthens.Relatively there was no significant difference of F group and C, D group, illustrates between the effect of IL-1 content in glucosamine hydrochloride Capsule in Reducing rabbit joint fluid between high, the middle dosage group of Chinese medicine.
IL-6 content results in joint fluid: in table 3, A group has significant difference with B group, and modeling success is described.B group and C, D, E, F group relatively have significant difference, illustrate that each treatment group all can significantly reduce the content of IL-6 in rabbit joint fluid.Between C, D, E group, relatively have between two significant difference, illustrate that Chinese herb on the prevention group increases with dosage, the effect that reduces IL-6 content in rabbit joint fluid strengthens.F group and C, E have significant difference, and in prompting glucosamine hydrochloride Capsule in Reducing rabbit joint fluid, the effect of IL-6 content is better than Chinese medicine low dose group but too late Chinese medicine high dose group.F group and relatively there was no significant difference of D group, illustrate that the effect of IL-6 content in glucosamine hydrochloride Capsule in Reducing rabbit joint fluid is identical with dosage group in Chinese medicine.
Illustrate that Chinese medicine composition of the present invention may treat early stage osteoarthritis by reducing IL-1, IL-6 level.
The impact of table 2 medicine of the present invention on IL-1 content in rabbit joint fluid
| Group | Number of cases | IL-1（ng/L） |
| A group (blank group) | 12 | 8.604±0.900※ |
| B group (model control group) | 12 | 321.583±86.050▲ |
| C group (Chinese medicine high dose group) | 12 | 91.213±4.321* |
| D group (dosage group in Chinese medicine) | 12 | 124.767±1.780* |
| E group (Chinese medicine low dose group) | 12 | 158.1250±11.191* |
| F group (glucosamine hydrochloride Capsules group) | 12 | 113.338±10.512★□ |
Note: A group and relatively ※ P<0.05 of B group; B group and C, D, E, F organize comparison ▲ P<0.05; F group and relatively ★ P<0.05 of E group; Between C, D, E group, compare between two * P<0.05; F group and C, relatively P>0.05 of D group.P value represents statistical value; P<0.05 representative has statistical significance; P>0.05 represents not statistically significant.
The impact of table 3 medicine of the present invention on IL-6 content in rabbit joint fluid
| Group | Number of cases | IL-1（ng/L） |
| A group (blank group) | 12 | 0.096±0.125※ |
| B group (model control group) | 12 | 249.958±37.199▲ |
| C group (Chinese medicine high dose group) | 12 | 47.446±17.374* |
| D group (dosage group in Chinese medicine) | 12 | 98.950±11.943* |
| E group (Chinese medicine low dose group) | 12 | 157.879±16.333* |
| F group (glucosamine hydrochloride Capsules group) | 12 | 98.329±12.309★□ |
Note: A group and relatively ※ P<0.05 of B group; B group and C, D, E, F organize comparison ▲ P<0.05; Between C, D, E group, compare between two * P<0.05; F group and C, relatively ★ P<0.05 of E group; F group and relatively P>0.05 of D group.P value represents statistical value; P<0.05 representative has statistical significance; P>0.05 represents not statistically significant.
Five, clinical observation
1) this organizes 40 examples, male 16 examples, female's 24 examples; One-sided 24 examples, bilateral 16 examples; Age 45-78 year, average 58.5 years old; Medical history March-10 year.Diagnosis basis: mostly 1. be middle-aged and elderly people; 2. symptom: the knee joint peripheral pain of outbreak repeatedly, when knee joint is born a heavy burden, pain increases the weight of, time have swelling, or have the slight Varus deformity of knee joint, sometimes have lower limb to beat soft or strand lock phenomenon; 3. sign: while bending and stretching knee joint, there is coarse joint crepitus more, floating patella test positive or negative, patella tenderness or the patella grinding test positive, joint motion is slightly limited; 4. x-ray inspection, grade scale: 0 grade (normally); I level (slight hyperosteogeny); II level (obviously hyperosteogeny, joint space is suspicious to narrow); III level (a large amount of hyperosteogenys, joint space obviously narrows, Subchondral bone sclerosis); IV level (a large amount of hyperosteogenys, joint space obviously narrows, serious Subchondral bone sclerosis and obviously deformity).This group I level 13 examples, II level 10 examples, III level 13 examples, IV level 4 examples.5. rheumatoid arthritis except.
2), Therapeutic Method: capsule prepared by oral this Chinese medicine composition, one time 4～6, every containing crude drug 0.4g, 3 times on the one, one after each meal, two weeks was 1 course for the treatment of.
3), efficacy assessment standard
Recovery from illness: knee joint disappearances of swelling and ache, functional activity recovers normally, after work, not recur; Effective: knee joint swells and ache and obviously alleviates, and functional activity recovers substantially, but walking makes not energetically for a long time, meets recurrence caused by overexertion and sends out; Effective: knee joint swells and ache and alleviates to some extent, and functional activity is improved; Invalid: unchanged before and after treatment.
4), result
As table 4, this organizes 40 examples, recovery from illness 15 examples, effective 22 examples, effective 3 examples, total effective rate 100%.
Table 4
| Rank | Total number of cases | Recovery from illness (example) | Effective (example) | Effectively (example) |
| I level | 13 examples | 10 | 3 | ? |
| II level | 10 examples | 5 | 5 | ? |
| III level | 13 examples | 0 | 11 | 2 |
| IV level | 4 examples | 0 | 3 | 1 |
Embodiment 1
Step 1,
Take Radix Rehmanniae Preparata 100g, Herba Cistanches 80g, Rhizoma Drynariae 100g, Herba Epimedii 100g, Radix Angelicae Sinensis 80g, Radix Paeoniae Alba 120g, Radix Astragali 100g, Radix Glycyrrhizae 60g, Radix Achyranthis Bidentatae 100g;
Step 2,
Herba Cistanches is dried and crushed into 100 object fine powders for subsequent use;
Step 3,
Radix Rehmanniae Preparata, Rhizoma Drynariae, Herba Epimedii, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Astragali, Radix Glycyrrhizae and Radix Achyranthis Bidentatae eight taste Chinese medicines are added to decocting to be carried twice, add for the first time the decocting of 10 times of amounts of eight taste Chinese medicine total amounts to boil 2 hours, filter, add for the second time the decocting of 8 times of amounts of eight taste Chinese medicine total amounts to boil 1.5 hours, filter, merge filtrate twice, then filtrate is evaporated to relative density at 50 DEG C is 1.35-1.40 thick paste;
Step 4,
Thick paste is mixed with Herba Cistanches fine powder and receive cream, be dried and crushed into 100 object medicated powder, then in medicated powder, add newborn sugar and starch, mix and obtain mixture, the percentage by weight that control lactose accounts for whole mixture is 8%, and the percentage by weight that control starch accounts for whole mixture is 10%; Finally granulate, 60 DEG C of low temperature are dry, and granulate, makes capsule, subpackage and get final product, and every capsules is containing crude drug 0.4g.
Embodiment 2
Step 1,
Take Radix Rehmanniae Preparata 150g, Herba Cistanches 100g, Rhizoma Drynariae 150g, Herba Epimedii 150g, Radix Angelicae Sinensis 80g, Radix Paeoniae Alba 120g, Radix Astragali 150g, Radix Glycyrrhizae 60g, Radix Achyranthis Bidentatae 100g;
Step 2,
Herba Cistanches is dried and crushed into 100 object fine powders for subsequent use;
Step 3,
Radix Rehmanniae Preparata, Rhizoma Drynariae, Herba Epimedii, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Astragali, Radix Glycyrrhizae and Radix Achyranthis Bidentatae eight taste Chinese medicines are added to decocting to be carried twice, add for the first time the decocting of 10 times of amounts of eight taste Chinese medicine total amounts to boil 2 hours, filter, add for the second time the decocting of 8 times of amounts of eight taste Chinese medicine total amounts to boil 1.5 hours, filter, merge filtrate twice, then filtrate is evaporated to relative density at 50 DEG C is 1.35-1.40 thick paste;
Step 4,
Thick paste is mixed with Herba Cistanches fine powder and receive cream, be dried and crushed into 100 object medicated powder, in medicated powder, add newborn sugar and starch, mix and obtain mixture, the percentage by weight that control lactose accounts for whole mixture is 10%, and the percentage by weight that control starch accounts for whole mixture is 10%; Finally granulate, 60 DEG C of low temperature are dry, and granulate, makes capsule, subpackage and get final product, and every capsules is containing crude drug 0.4g.
Embodiment 3
Step 1,
Take Radix Rehmanniae Preparata 150g, Herba Cistanches 70g, Rhizoma Drynariae 90g, Herba Epimedii 90g, Radix Angelicae Sinensis 60g, Radix Paeoniae Alba 150g, Radix Astragali 150g, Radix Glycyrrhizae 90g, Radix Achyranthis Bidentatae 150g;
Step 2,
Herba Cistanches is dried and crushed into 80 object fine powders for subsequent use;
Step 3,
Radix Rehmanniae Preparata, Rhizoma Drynariae, Herba Epimedii, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Astragali, Radix Glycyrrhizae and Radix Achyranthis Bidentatae eight taste Chinese medicines are added to decocting to be carried twice, add for the first time the decocting of 8 times of amounts of eight taste Chinese medicine total amounts to boil 1 hour, filter, add for the second time the decocting of 10 times of amounts of eight taste Chinese medicine total amounts to boil 2 hours, filter, merge filtrate twice, then filtrate is evaporated to relative density at 50 DEG C is 1.35-1.40 thick paste;
Step 4,
Thick paste is mixed with Herba Cistanches fine powder and receive cream, be dried and crushed into 80 object medicated powder, in medicated powder, add newborn sugar and starch, mix and obtain mixture, the percentage by weight that control lactose accounts for whole mixture is 9%, and the percentage by weight that control starch accounts for whole mixture is 9%; Finally granulate, 60 DEG C of low temperature are dry, and granulate, makes capsule, subpackage and get final product, and every capsules is containing crude drug 0.4g.
Embodiment 4
Step 1,
Take Radix Rehmanniae Preparata 90g, Herba Cistanches 140g, Rhizoma Drynariae 150g, Herba Epimedii 150g, Radix Angelicae Sinensis 130g, Radix Paeoniae Alba 110g, Radix Astragali 90g, Radix Glycyrrhizae 50g, Radix Achyranthis Bidentatae 90g;
Step 2,
Herba Cistanches is dried and crushed into 120 object fine powders for subsequent use;
Step 3,
Radix Rehmanniae Preparata, Rhizoma Drynariae, Herba Epimedii, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Astragali, Radix Glycyrrhizae and Radix Achyranthis Bidentatae eight taste Chinese medicines are added to decocting to be carried twice, add for the first time the decocting of 12 times of amounts of eight taste Chinese medicine total amounts to boil 3 hours, filter, add for the second time the decocting of 6 times of amounts of eight taste Chinese medicine total amounts to boil 1 hour, filter, merge filtrate twice, then filtrate is evaporated to relative density at 50 DEG C is 1.35-1.40 thick paste;
Step 4,
Thick paste is mixed with Herba Cistanches fine powder and receive cream, be dried and crushed into 120 object medicated powder, then in medicated powder, add starch, mix and obtain mixture, the percentage by weight that control starch accounts for whole mixture is 8%; Finally granulate, dry, compacting in flakes, makes tablet.
Claims (4)
1. the Chinese medicine composition for the treatment of gonalgia osteoarthritis, is characterized in that, by weight percentage, formed by the raw material of Chinese medicine of making below active ingredient: Radix Rehmanniae Preparata 9-15%, Herba Cistanches 7-14%, Rhizoma Drynariae 9-15%, Herba Epimedii 9-15%, Radix Angelicae Sinensis 6-13%, the Radix Paeoniae Alba 11-15%, Radix Astragali 9-15%, Radix Glycyrrhizae 5-9%, Radix Achyranthis Bidentatae 9-15%, above each component percentage by weight sum is 100%.
2. a preparation method for Chinese medicine composition described in claim 1, is characterized in that, comprises following operating procedure:
Step 1,
Take each raw material according to following percentage by weight: Radix Rehmanniae Preparata 9-15%, Herba Cistanches 7-14%, Rhizoma Drynariae 9-15%, Herba Epimedii 9-15%, Radix Angelicae Sinensis 6-13%, the Radix Paeoniae Alba 11-15%, Radix Astragali 9-15%, Radix Glycyrrhizae 5-9%, Radix Achyranthis Bidentatae 9-15%, above each component percentage by weight sum is 100%;
Step 2,
Herba Cistanches is dried and crushed into 80-120 object fine powders for subsequent use;
Step 3,
Radix Rehmanniae Preparata, Rhizoma Drynariae, Herba Epimedii, Radix Angelicae Sinensis, the Radix Paeoniae Alba, Radix Astragali, Radix Glycyrrhizae and Radix Achyranthis Bidentatae eight taste Chinese medicines are added to decocting to be carried twice, add for the first time the decocting of 8-12 times of amounts of eight taste Chinese medicine total amounts to boil 1-3 hours, filter, add for the second time the decocting of 6-10 times of amounts of eight taste Chinese medicine total amounts to boil 1-2 hours, filter, merge filtrate twice, then filtrate is evaporated to relative density at 50 DEG C is 1.35-1.40 thick paste;
Step 4,
Thick paste is mixed with Herba Cistanches fine powder and receive cream, be dried and crushed into 80-120 object medicated powder, to obtain final product.
3. the preparation method of Chinese medicine composition according to claim 2, is characterized in that: in the medicated powder making in step 4, add newborn sugar and starch, mix, granulate, dry, granulate, makes capsule.
4. the preparation method of Chinese medicine composition according to claim 2, is characterized in that: in the medicated powder making in step 4, add starch, mix, granulate, dry, compacting in flakes, makes tablet.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010190202.9A CN101926878B (en) | 2010-06-03 | 2010-06-03 | Chinese medicinal composition for treating osteoarthritis and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201010190202.9A CN101926878B (en) | 2010-06-03 | 2010-06-03 | Chinese medicinal composition for treating osteoarthritis and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101926878A CN101926878A (en) | 2010-12-29 |
| CN101926878B true CN101926878B (en) | 2014-10-29 |
Family
ID=43366481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201010190202.9A Active CN101926878B (en) | 2010-06-03 | 2010-06-03 | Chinese medicinal composition for treating osteoarthritis and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101926878B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103083443B (en) * | 2012-03-05 | 2014-04-23 | 湖南中医药大学 | Chinese medicinal composition for treating arthritis and preparation method thereof |
| CN105477193A (en) * | 2015-12-25 | 2016-04-13 | 范明月 | Traditional Chinese medicine powder for treating osteoarthritis and preparation method thereof |
| CN105412437A (en) * | 2015-12-25 | 2016-03-23 | 范明月 | Traditional Chinese medicine for treating osteoarthritis and preparing method of traditional Chinese medicine |
| CN105381272A (en) * | 2015-12-25 | 2016-03-09 | 范明月 | Traditional Chinese medicine decoction for treating osteoarthritis and preparation method thereof |
| CN110075243A (en) * | 2019-05-14 | 2019-08-02 | 林畅 | A kind of Traditional Chinese medicine composition having effects of tonifying kidney and dredging collaterals and its preparation method and application |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1411829A (en) * | 2001-10-17 | 2003-04-23 | 宋大文 | Medicine for curing proliferation arthritis of spine and its preparation method |
| CN1895594A (en) * | 2005-07-15 | 2007-01-17 | 张庆华 | Medicine for treating arthritis and its preparation |
| CN101380453A (en) * | 2008-07-21 | 2009-03-11 | 刘翠侠 | Oral powder and external plaster for treating hyperosteogeny and atrophic arthritis and production method thereof |
| CN102283938A (en) * | 2011-06-08 | 2011-12-21 | 郭成根 | Medicinal liquor for treating primary osteoarthritis and cervical and lumbar disc herniation, and preparation method thereof |
| CN102416046A (en) * | 2011-12-13 | 2012-04-18 | 李晓春 | Traditional Chinese medicine preparation for treating osteoarthritis |
-
2010
- 2010-06-03 CN CN201010190202.9A patent/CN101926878B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1411829A (en) * | 2001-10-17 | 2003-04-23 | 宋大文 | Medicine for curing proliferation arthritis of spine and its preparation method |
| CN1895594A (en) * | 2005-07-15 | 2007-01-17 | 张庆华 | Medicine for treating arthritis and its preparation |
| CN101380453A (en) * | 2008-07-21 | 2009-03-11 | 刘翠侠 | Oral powder and external plaster for treating hyperosteogeny and atrophic arthritis and production method thereof |
| CN102283938A (en) * | 2011-06-08 | 2011-12-21 | 郭成根 | Medicinal liquor for treating primary osteoarthritis and cervical and lumbar disc herniation, and preparation method thereof |
| CN102416046A (en) * | 2011-12-13 | 2012-04-18 | 李晓春 | Traditional Chinese medicine preparation for treating osteoarthritis |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101926878A (en) | 2010-12-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101181453A (en) | Chinese medicine preparation for curing orthopaedics sickness | |
| CN101926878B (en) | Chinese medicinal composition for treating osteoarthritis and preparation method thereof | |
| CN103263659B (en) | Traditional Chinese medicine composition for treating rheumatism bone diseases | |
| CN100394955C (en) | Chinese traditional medicine preparation for treating bone fracture and traumatic injury | |
| CN107468768B (en) | Qiang medicine composition and application thereof | |
| CN103610982B (en) | A kind of medicine for the treatment of rheumatic arthritis | |
| CN103520682A (en) | Traditional Chinese medicine composition for treating rheumatism bone disease | |
| CN105832991A (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN101904958B (en) | Oral medicinal composition for treating fracture | |
| CN100344318C (en) | Medicine for treating apoplectic sequel and prepn. thereof | |
| CN100509028C (en) | Purge capsules for old person and production thereof | |
| CN102614344B (en) | Traditional Chinese medicine for treating qi-blood deficiency periodontitis, preparation method and administration method thereof | |
| CN103169745A (en) | Traditional Chinese medicine composition for treating hematuria and application thereof | |
| CN1415359A (en) | Health foods for tonification, being sturdy and postponing senility | |
| CN105327121A (en) | Traditional Chinese medicine composition for treating female postmenopausal osteoporosis and preparing method thereof | |
| CN100367997C (en) | Medicine for treating arthrolithiasis and preparing method thereof | |
| CN103585414A (en) | Pharmaceutical composition for treating sciatica and osteoporosis | |
| CN100342871C (en) | Painful impediment capsule and its preparation method | |
| CN1718218A (en) | Medicine for treating osteoarthritis, and its prepn. method | |
| TW201406383A (en) | Chinese medicine composition for treating muscular dystrophy, joint deformation and uric acid gout, and preparation method thereof | |
| CN107982409B (en) | Traditional Chinese medicine composition and pill for treating syringomyelia and preparation method thereof | |
| CN103083459B (en) | Traditional Chinese medicinal compound preparation for treating constipation, and preparation method and application thereof | |
| CN1325103C (en) | Tendon and bone strengthening capsule | |
| CN105343862A (en) | Drug composition for soft tissue injury and fracture | |
| CN105079239B (en) | A kind of granule for treating osteoproliferation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |